How, Soon Hin and Tho, Lye Mun and Liam, Chong Kin and Hasbullah, Harissa H. and Ho, Gwo Fuang and Nor, Ibtisam Muhammad and Poh, Mau Ern and Ho, Kean Fatt and Thiagarajan, Muthukkumaran and Samsudin, Azlina and Omar, Azza and Ong, Choo Khoon and Pang, Yong Kek and Soon, Sing Yang (2022) Programmed death-ligand 1 expression and use of immune checkpoint inhibitors among patients with advanced non-small-cell lung cancer in a resource-limited country. Thoracic Cancer, 13 (11). pp. 1676-1683. ISSN 1759-7706, DOI https://doi.org/10.1111/1759-7714.14442.
Full text not available from this repository.Abstract
Introduction Immune checkpoint inhibitor (ICI) therapy is an established treatment for advanced non-small-cell lung cancer (NSCLC) and programmed death ligand-1 (PD-L1) expression is a recognized biomarker to determine response to therapy. We retrospectively analyzed NSCLC patients in the Malaysia Lung Cancer Registry (MLCR) and report on the clinical characteristics associated with PD-L1 expression and ICI use in Malaysia, a low- to middle-income country. Methods All 901 NSCLC patients in the MLCR who were diagnosed from January 1, 2017 to December 31, 2020 from 14 hospitals across the country were analyzed. Results Out of 901 patients, 505 had PDL-1 testing done with complete data available only in 489 patients. The most common histology was adenocarcinoma (84.7%) followed by squamous cell carcinoma (10.2%). The majority (95%) presented with stage 3 or 4. The number and percentage of patients with PDL-1 tumor proportion scores of >= 50%, 1-49%, and <1% were 138 (28.2%), 158 (32.3%), and 193 (39.5%), respectively. In multivariate analysis, the presence of genomic mutation is the only independent characteristic associated with negative PD-L1 expression (crude odds ratio 0.579, 95% confidence interval 0.399-0.840, p = 0.004). Of 292 patients eligible for ICI therapy, only 100 patients (34.2%) received ICIs. Seventy-eight patients received ICI therapy as first-line treatment, 15 patients as second-line treatment, and 7 patients as third-line treatment. Conclusions This is the first analysis on PD-L1 expression and ICI use in Malaysia. Despite the proven efficacy of ICI therapy, only 56% of our patients had PD-L1 tests performed and only 34.2% of eligible patients received ICIs.
| Item Type: | Article |
|---|---|
| Funders: | Malaysian Thoracic Society, Malaysian Association for Thoracic & Cardiovascular Surgery |
| Uncontrolled Keywords: | PDL-1; Immunotherapy; Lung cancer |
| Subjects: | R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) R Medicine > RD Surgery |
| Divisions: | Faculty of Medicine |
| Depositing User: | Ms. Juhaida Abd Rahim |
| Date Deposited: | 12 Oct 2023 03:28 |
| Last Modified: | 12 Oct 2023 03:28 |
| URI: | http://eprints.um.edu.my/id/eprint/42216 |
Actions (login required)
 |
View Item |
